TY - JOUR
T1 - The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program
T2 - Reliability and stability of measures
AU - Mathalon, Daniel H.
AU - Nicholas, Spero
AU - Roach, Brian J.
AU - Billah, Tashrif
AU - Lavoie, Suzie
AU - Whitford, Thomas
AU - Hamilton, Holly K.
AU - Addamo, Lauren
AU - Anohkin, Andrey
AU - Bekinschtein, Tristan
AU - Belger, Aysenil
AU - Buccilli, Kate
AU - Cahill, John
AU - Carrión, Ricardo E.
AU - Damiani, Stefano
AU - Dzafic, Ilvana
AU - Ebdrup, Bjørn H.
AU - Izyurov, Igor
AU - Jarcho, Johanna
AU - Jenni, Raoul
AU - Jo, Anna
AU - Kerins, Sarah
AU - Lee, Clarice
AU - Martin, Elizabeth A.
AU - Mayol-Troncoso, Rocio
AU - Niznikiewicz, Margaret A.
AU - Parvaz, Muhammad
AU - Pogarell, Oliver
AU - Prieto-Montalvo, Julio
AU - Rabin, Rachel
AU - Roalf, David R.
AU - Rogers, Jack
AU - Salisbury, Dean F.
AU - Shaik, Riaz
AU - Shankman, Stewart
AU - Stevens, Michael C.
AU - Suen, Yi Nam
AU - Swann, Nicole C.
AU - Tang, Xiaochen
AU - Thompson, Judy L.
AU - Tso, Ivy
AU - Wenzel, Julian
AU - Zhou, Juan Helen
AU - Addington, Jean
AU - Alameda, Luis
AU - Arango, Celso
AU - Breitborde, Nicholas J.K.
AU - Broome, Matthew R.
AU - Cadenhead, Kristin S.
AU - Kahn, Rene S.
N1 - Publisher Copyright:
© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2025.
PY - 2025/6/6
Y1 - 2025/6/6
N2 - Individuals at clinical high risk for psychosis (CHR) have variable clinical outcomes and low conversion rates, limiting development of novel and personalized treatments. Moreover, given risks of antipsychotic drugs, safer effective medications for CHR individuals are needed. The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Program was launched to address this need. Based on past CHR and schizophrenia studies, AMP SCZ assessed electroencephalography (EEG)-based event-related potential (ERP), event-related oscillation (ERO), and resting EEG power spectral density (PSD) measures, including mismatch negativity (MMN), auditory and visual P300 to target (P3b) and novel (P3a) stimuli, 40-Hz auditory steady state response, and resting EEG PSD for traditional frequency bands (eyes open/closed). Here, in an interim analysis of AMP SCZ EEG measures, we assess test-retest reliability and stability over sessions (baseline, month-2 follow-up) in CHR (n = 654) and community control (CON; n = 87) participants. Reliability was calculated as Generalizability (G)-coefficients, and changes over session were assessed with paired t-tests. G-coefficients were generally good to excellent in both groups (CHR: mean = 0.72, range = 0.49–0.85; CON: mean = 0.71, range = 0.44–0.89). Measure magnitudes significantly (p < 0.001) decreased over session (MMN, auditory and visual target P3b, visual novel P3a, 40-Hz ASSR) and/or over runs within sessions (MMN, auditory/visual novel P3a and target P3b), consistent with habituation effects. Despite these small systematic habituation effects, test-retest reliabilities of the AMP SCZ EEG-based measures are sufficiently strong to support their use in CHR studies as potential predictors of clinical outcomes, markers of illness progression, and/or target engagement or secondary outcome measures in controlled clinical trials.
AB - Individuals at clinical high risk for psychosis (CHR) have variable clinical outcomes and low conversion rates, limiting development of novel and personalized treatments. Moreover, given risks of antipsychotic drugs, safer effective medications for CHR individuals are needed. The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Program was launched to address this need. Based on past CHR and schizophrenia studies, AMP SCZ assessed electroencephalography (EEG)-based event-related potential (ERP), event-related oscillation (ERO), and resting EEG power spectral density (PSD) measures, including mismatch negativity (MMN), auditory and visual P300 to target (P3b) and novel (P3a) stimuli, 40-Hz auditory steady state response, and resting EEG PSD for traditional frequency bands (eyes open/closed). Here, in an interim analysis of AMP SCZ EEG measures, we assess test-retest reliability and stability over sessions (baseline, month-2 follow-up) in CHR (n = 654) and community control (CON; n = 87) participants. Reliability was calculated as Generalizability (G)-coefficients, and changes over session were assessed with paired t-tests. G-coefficients were generally good to excellent in both groups (CHR: mean = 0.72, range = 0.49–0.85; CON: mean = 0.71, range = 0.44–0.89). Measure magnitudes significantly (p < 0.001) decreased over session (MMN, auditory and visual target P3b, visual novel P3a, 40-Hz ASSR) and/or over runs within sessions (MMN, auditory/visual novel P3a and target P3b), consistent with habituation effects. Despite these small systematic habituation effects, test-retest reliabilities of the AMP SCZ EEG-based measures are sufficiently strong to support their use in CHR studies as potential predictors of clinical outcomes, markers of illness progression, and/or target engagement or secondary outcome measures in controlled clinical trials.
UR - https://www.scopus.com/pages/publications/105007724846
U2 - 10.1038/s41537-025-00622-0
DO - 10.1038/s41537-025-00622-0
M3 - Article
AN - SCOPUS:105007724846
SN - 2754-6993
VL - 11
JO - Schizophrenia
JF - Schizophrenia
IS - 1
M1 - 85
ER -